A phase I study of the HDM2 antagonist SAR405838 combined with the MEK inhibitor pimasertib in patients with advanced solid tumours
de Weger, Vincent A., de Jonge, Maja, Langenberg, Marlies H. G., Schellens, Jan H. M., Lolkema, Martijn, Varga, Andrea, Demers, Brigitte, Thomas, Koruth, Hsu, Karl, Tuffal, Gilles, Goodstal, Samantha,Language:
english
Journal:
British Journal of Cancer
DOI:
10.1038/s41416-018-0355-8
Date:
December, 2018
File:
PDF, 424 KB
english, 2018